Health-related quality of life in non-small-cell lung cancer: Methodologic issues in randomized controlled trials

Journal of Clinical Oncology

Volumn 21, Issue 15, 2003, Pages 2982-2992

  Bottomley, Andrew ^a   Efficace, Fabio ^a   Thomas, Ronald ^a   Vanvoorden, Veerle ^a   Ahmedzai, Sam H ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER MORTALITY; CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HUMAN; LUNG NON SMALL CELL CANCER; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SYSTEMATIC REVIEW; LUNG TUMOR; METHODOLOGY;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN;

EID: 0042887522     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.01.203     Document Type: Review

References (60)

1. Parkin DM: Global cancer statistics in the year 2000. Lancet Oncol 2:533-542, 2001
2. Ihde DC: Chemotherapy of lung cancer. N Engl J Med 327:1434-1441, 1992
3. Hansen HH, Pappot H: Primary malignant tumors of the lung and pleura, in Cavalli F, Hansen HH, Kaye SB (eds): Textbook of Medical Oncology. London, United Kingdom, Martin Dunit, 2000, pp 245-270
4. Staquet MJ, Hayes RD, Fayers PM: Quality of Life Assessment in Clinical Trials: Methods and Practices. Oxford, United Kingdom, Oxford University Press, 1998
5. Kosmidis P: Quality of life as a new end point. Chest 109:S110-S112, 1996 (suppl 5)
6. Sarna L, Padilla G, Holmes C, et al: Quality of life of long-term survivors of non-small cell lung cancer. J Clin Oncol 20:2920-2929, 2002
7. Hawson G, Zimmerman PV, Ford CA, et al: Primary lung cancer: Characterization and survival of 1024 patients treated in a single institution. Med J Aust 152:230-234, 1990
8. Klastersky J, Paesmans M: Response to chemotherapy, quality of life benefits and survival in advanced non-small cell lung cancer: Review of literature results. Lung Cancer 34:95-101, 2001 (suppl 4)
9. American Society of Clinical Oncology: Clinical practice guidelines for the treatment of unresectable non-small cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology. J Clin Oncol 15:2996-3018, 1997
10. Non-Small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 311:899-909, 1995
11. PORT Meta-Analysis Trialists Group: Postoperative radiotherapy in non-small cell lung cancer: Systematic review and meta-analysis of individual patient data from nine randomized controlled trials. Lancet 352:257-263, 1998
12. Lilenbaum RC, List M, Desch C: Single-agent versus combination chemotherapy in advanced non-small cell lung cancer: A meta-analysis and the Cancer and Leukemia Group B randomized trial. Semin Oncol 26:52-54, 1999
13. Sorenson S, Glimelius B, Nygren P: A systematic overview of chemotherapy effects in non-small cell lung cancer. Acta Oncol 40:327-339, 2001
14. Lee CW, Chi KN: The standard of reporting of health-related quality of life in clinical cancer trials. J Clin Epidemiol 53:451-458, 2000
15. Sanders C, Egger M, Donovan J, et al: Reporting on quality of life in randomized controlled trials: Bibliographic study. BMJ 317:1191-1194, 1998
16. Fayers PM, Machin D: Quality of life: Assessment, analysis and interpretation. Chichester, United Kingdom, John Wiley & Sons, 2000
17. Sterne JA, Egger M, Smith GD: Systematic reviews in health care: Investigating and dealing with publication and other biases in meta-analysis. BMJ 323:101-105, 2001
18. Staquet M, Berzon R, Osoba D, et al: Guidelines for reporting results of quality of life assessments in clinical trials. Qual Life Res 5:496-502, 1996
19. Juni P, Alterman DG, Egger M: Assessing the quality of systematic reviews. BMJ 323:42-46, 2001
20. Simes RJ: Confronting publication bias: A cohort design for metaanalysis. Stat Med 6:11-26, 1987
21. De Bellefeuille C, Morrison CA, Tannock IF: The fate of abstracts submitted to a cancer meeting: Factors which influence presentation and subsequent publication. Ann Oncol 3:187-191, 1992
22. Hopewell S, Clarke M: Methodologists and their methods: Do methodologists write up their conference presentations or is it just 15 minutes of fame? Int J Technol Assess Health Care 17:601-603, 2001
23. Efficace F, Bottomley A, van Andel G: Health-related quality of life in prostate carcinoma patients: A systematic review of randomized controlled trials. Cancer 97:377-388, 2003
24. Buccheri GF, Ferrigno D, Curcio A, et al: Continuation of chemotherapy versus supportive care alone in patients with inoperable non-small cell lung cancer and stable disease after two or three cycles of MACC: Results of a randomized prospective study. Cancer 63:428-432, 1989
25. Report to the Medical Research Council by its Lung Cancer Working Party: Inoperable non-small cell lung cancer (NSCLC): A Medical Research Council randomized trial of palliative radiotherapy with two fractions or ten fractions. Br J Cancer 63:265-270, 1991
26. Kosty MP, Fleishman SB, Herndon JE, et al: Cisplatin, vinblastine, and hydrazine sulfate in advanced, non-small cell lung cancer: A randomized placebo-controlled, double-blind phase III study of the Cancer and Leukemia Group B. J Clin Oncol 12:1113-1120, 1994
27. Herndon JE, Fleishman S, Kosty MP, et al: A longitudinal study of quality of life in advanced non-small cell lung cancer: Cancer and Leukemia Group B (CALGB) 8931. Control Clin Trials 18:286-300, 1997
28. Buccheri G, Ferrigno D: Efficacy of platinum-based regimens in non-small cell lung cancer: A negative report from the Cuneo Lung Cancer Study Group. Lung Cancer 18:57-70, 1997
29. Ball D, Smith J, Bishop J, et al: A phase III study of radiotherapy with and without continuous-infusion fluorouracil as palliation for non-small cell lung cancer. Br J Cancer 75:690-697, 1997
30. Giaccone G, Splinter TA, Debruyne C, et al: Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small cell lung cancer: The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 16:2133-2141, 1998
31. ten Bokkel Huinink WW, Bergman B, Chemaissani A, et al: Single-agent gemcitabine: An active and better tolerated alternative to standard cisplatin-based chemotherapy in locally advanced or metastatic non-small cell lung cancer. Lung Cancer 26:85-94, 1999
32. Cullen MH, Billingham LJ, Woodroffe CM, et al: Mitomycin, ifosfamide, and cisplatin in unresectable non-small cell lung cancer: Effects on survival and quality of life. J Clin Oncol 17:3188-3194, 1999
33. Crinò L, Scagliotti GV, Ricci S, et al: Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol 17:3522-3530, 1999
34. Anderson H, Hopwood P, Stephens RJ, et al: Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer: A randomized trial with quality of life as the primary outcome-UK NSCLC Gemcitabine Group Non-Small Cell Lung Cancer. Br J Cancer 83:447-453, 2000
35. Smith IE, O'Brien ME, Talbot DC, et al: Duration of chemotherapy in advanced non-small cell lung cancer: A randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol 19:1336-1343, 2001
36. Kelly K, Crowley J, Bunn PA Jr, et al: Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer: A Southwest Oncology Group trial. J Clin Oncol 19:3210-3218, 2001
37. Socinski MA, Schell MJ, Peterman A, et al: Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol 20:1335-1343, 2002
38. Gatzemeier U, von Pawel J, Gottfried M, et al: Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 18:3390-3399, 2000
39. Cardenal F, Lopez-Cabrerizo MP, Anton A, et al: Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 17:12-18, 1999
40. Cornella P, Frasci G, Panza N, et al: Cisplatin, gemcitabine, and vinorelbine combination therapy in advanced non-small cell lung cancer: A phase II randomized study of the Southern Italy Cooperative Oncology Group. J Clin Oncol 17:1526-1534, 1999
41. Gridelli C, Frontini L, Perrone F, et al: Gemcitabine plus vinorelbine in advanced non-small cell lung cancer: A phase II study of three different doses-Gem Vin Investigators. Br J Cancer 83:707-714, 2000
42. Macbeth FR, Bolger JJ, Hopwood P, et al: Randomized trial of palliative two-fraction versus more intensive 13-fraction radiotherapy for patients with inoperable non-small cell lung cancer and good performance status. Medical Research Council Lung Cancer Working Party. Clin Oncol (R Coll Radiol) 8:167-175, 1996
43. Crawford J, O'Rourke M, Schiller JH, et al: Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small cell lung cancer. J Clin Oncol 14:2774-2784, 1996
44. Bailey AJ, Parmar MK, Stephens RJ: Patient-reported short-term and long-term physical and psychologic symptoms: Results of the continuous hyperfractionated accelerated [correction of accelerated] radiotherapy (CHART) randomized trial in non-small cell lung cancer. CHART Steering Committee. J Clin Oncol 16:3082-3093, 1998
45. Saunders M, Dische S, Barrett A, et al: Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: A randomised multicentre trial. Lancet 350:161-165, 1997
46. The Elderly Lung Cancer Vinorelbine Italian Study Group: Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer. J Natl Cancer Inst 91:66-72, 1999
47. Thongprasert S, Sanguanmitra P, Juthapan W, et al: Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: Best supportive care (BSC) versus BSC plus chemotherapy. Lung Cancer 24:17-24, 1999
48. Shepherd FA, Dancey J, Ramlau R, et al: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18:2095-2103, 2000
49. Bonomi P, Kim K, Fairclough D, et al: Comparison of survival and quality of life in advanced non-small cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 18:623-631, 2000
50. Frasci G, Lorusso V, Panza N, et al: Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small cell lung cancer. J Clin Oncol 18:2529-2536, 2000
51. Sandier AB, Nemunaitis J, Denham C, et al: Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 18:122-130, 2000
52. Ranson M, Davidson N, Nicolson M, et al: Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small cell lung cancer. J Natl Cancer Inst 92:1074-1080, 2000
53. Roszkowski K, Pluzanska A, Krzakowski M, et al: A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer 27:145-157, 2000
54. Efficace F, Bottomley A: Health-related quality of life assessment methodology and reported outcomes in randomised controlled trials of primary brain cancer patients. Eur J Cancer 38:1824-1831, 2002
55. Bottomley A, Thomas R, Van Steen K, et al: Human recombinant erythropoietin and quality of life: A wonder drug or something to wonder about? Lancet Oncol 3:145-153, 2002
56. Osoba D, Rodrigues G, Myles J, et al: Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16:139-144, 1998
57. Bodenheimer T: Uneasy alliance: Clinical investigators and the pharmaceutical industry. N Engl J Med 342:1539-1544, 2000
58. International Committee of Medical Journal Editors: Uniform requirements for manuscripts submitted to biomedical journals. International Committee of Medical Journal Editors. Ann Intern Med 126:36-47, 1997
59. Gross CP, Gupta AR, Krumholz HM: Disclosure of financial competing interests in randomized controlled trials: Cross sectional review. BMJ 326:526-527, 2003
60. Efficace F, Bottomley A, Osoba D, et al: The impact of health-related quality of life (HRQOL) assessment in prostate cancer research: Does it provide meaningful support for clinical decision-making? Proc Am Soc Clin Oncol 22:426, 2003 (abstr 1713)